Chemomab Therapeutics Ltd ADR CMMB

$1.40 -0.01 (-0.71%)

Valuation

Market cap
10,216,000
Revenue TTM
$0
Net income TTM
$-9,000,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
25,200
Avg volume
120,528
Day's range
$1.38 – $1.57
Shares out
7,246,000
Stochastic %K
28%
Beta
0.74
Analysts
Strong Sell
Price target
$5.00

Price

Company profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating prima...

Show more

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.

Industry
Biotechnology
Sector
Healthcare
Phone
972 77 331 0156
Website
https://www.chemomab.com
Address
Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel

Latest news

Stocktwits

Zdxss1 Oct 6, 6:33 PM
$CMMB "I will not sell my shares. There are possibilities of a better deal, even if it seems weak. If a better deal does not come, there are still CVR rights. As for those who are counting on the success of the new company, they know nothing about investing
0 replies
TechnoFunctional Oct 6, 4:19 PM
$CMMB ARKG biotech stocks are on fire, many of them are story stocks based on “AI Drug Discovery” and here we are bashing our Spectra AI Platform - pioneer in precision immunology for autoimmune disease. Had you all been not so negative Nelly we would have been at $10. Just kidding, I know everyone here is super pissed. My PF has just imploded in the last 1 month. :(
1 replies
cayman777 Oct 6, 2:16 PM
$CMMB
0 replies
Zdxss1 Oct 6, 1:51 PM
$CMMB While the merger deal itself is undeniably terrible, what is even worse is the strategic pivot from PSC to RA
1 replies
InvestorNOR Oct 6, 1:22 PM
$CMMB Even Grok have picked apart the Chemomab`s excuse at this point. We need to create hell now towards the board
0 replies
InvestorNOR Oct 6, 9:37 AM
$CMMB A lot is common with nebokitug. PSC and SSc drug. Go figure https://www.fiercebiotech.com/biotech/csl-pays-355m-co-develop-alentis-phase-2-stage-fibrosis-drug
2 replies
InvestorNOR Oct 6, 7:12 AM
$CMMB License out nebokitug for PSC cash upfront and continue operating as Chemomab while working on SSc and RA. License out nebokitug for RA for highest bidder for another cash offer and milestones. Work with SSc alone to move pipeline. Skip out licensing, sell the IP nebokitug and shut down the company. Get more cash upfront plus milestones for shareholders. I think we can all agree that ANY of these scenarios beat $10M divided on 8M shares in Scipher with a going concern language from the start. Im also certain that any of these deals will give shareholder minimum $40-50M cash directly to shareholders, not equity in a company market doesnt seem to believe in. Either Scipher’s PIPE contribute $50M cash and improve this story, or they risk launching the most broken merger in the history of mankind. PR is needed here to save the merger.
0 replies
cayman777 Oct 5, 11:31 PM
$CMMB
2 replies